Skip to search formSkip to main contentSkip to account menu

insulin aspart, insulin aspart protamine drug combination 30:70

Known as: BIAsp 30, biphasic insulin aspart 30:70, biphasic insulin aspart 30 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (4)

Biphasic InsulinsHypoglycemic AgentsInsulin Aspartinsulin, isophane

Narrower (1)

NovoLog Mix 70/30

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to…
Highly Cited
2014
Highly Cited
2014
Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial
OBJECTIVE Insulin degludec/insulin aspart (IDegAsp) is the first combination of a basal insulin with an ultralong duration of… 
Highly Cited
2009
Highly Cited
2009
Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix® 30) in routine care: safety and effectiveness in patients with type 2 diabetes in…
Aims:  The IMPROVE™ observational study evaluated the safety profile and effectiveness of biphasic insulin aspart 30/70 (BIAsp 30… 
2009
2009
Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes
Aim: This 3-month study compared the effect on overall glycemic control of adding biphasic insulin aspart 30 (BIAsp30) and… 
Highly Cited
2008
Highly Cited
2008
The IMPROVE™ study – a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts
Aims:  The IMPROVE™ study is a multinational, open‐label, non‐randomised, 26‐week observational study assessing the safety and… 
2008
2008
Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study
ABSTRACT Aim: The safety and efficacy of biphasic insulin aspart (BIAsp30) were evaluated in patients uncontrolled on previous… 
Highly Cited
2007
Highly Cited
2007
Using Continuous Glucose Monitoring to Measure the Frequency of Low Glucose Values When Using Biphasic Insulin Aspart 30 Compared With Biphasic Human Insulin 30
OBJECTIVE—Rapid-acting insulin analogs in basal-bolus regimens can reduce nocturnal hypoglycemia, so it is conceivable that twice… 
Highly Cited
2004
Highly Cited
2004
Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes.
Highly Cited
2003
Highly Cited
2003
Twice daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice daily NPH insulin, with low risk of hypoglycaemia, in patients with type 2 diabetes
Objective:  Biphasic insulin aspart 30 (BIAsp30) is a dual release formulation, containing 30% soluble and 70% protamine… 
Highly Cited
2000
Highly Cited
2000
Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart
AbstractObjective: With the aim to obtain a premixed rapid-acting insulin with a serum insulin profile more closely resembling… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)